Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-2829 and GS-6779 arenavirus vector vaccines in healthy volunteers and chronic hepatitis B patients
NCT05770895Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of GS-2829 and GS-6779 in Chronic Hepatitis B (CHB) (8 cohorts), sponsored by Gilead Sciences. Primary endpoints: Treatment-emergent Adverse Events, Serious Adverse Events and 1 more. Started Apr 2023; status: completed.
02
Drugs
GS-2829GS-6779
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05770895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770895.